Atara Biotherapeutics (ATRA) Other Accumulated Expenses (2013 - 2026)

Atara Biotherapeutics has reported Other Accumulated Expenses for 14 years, with the latest figure at $41000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 97.7% year-over-year to $41000.0; the trailing twelve-month figure through Mar 2026 stood at $41000.0 (down 97.7% YoY), and the FY2025 full-year result was $3.0 million, up 1277.78% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $41000.0, down from $3.0 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $26.1 million in Q2 2024, with the low at $41000.0 in Q1 2026.
• Historically, Other Accumulated Expenses has averaged $11.0 million across 5 years, with a median of $7.7 million in 2025.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses jumped 5343.26% — and 2024, when it slumped 98.76%.
• Atara Biotherapeutics' Other Accumulated Expenses stood at $319000.0 in 2022, then jumped by 5343.26% to $17.4 million in 2023, then tumbled by 98.76% to $216000.0 in 2024, then jumped by 1277.78% to $3.0 million in 2025, then slumped by 98.62% to $41000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $41000.0 (Q1 2026), $3.0 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.